Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System

No abstract is available for this paper.

• Publication year

  2016

• Venue

  HYPERTENSION

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/HYPERTENSIONAHA.116.07363PMID 27067721PMCID PMC4865437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function.

  2016cited by this paper
• Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.

  2015cited by this paper
• Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

  2012cited by this paper
• Notice

  2012cited by this paper
• Predictors of hyperkalemia and death in patients with cardiac and renal disease.

  2012cited by this paper
• Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan.

  2011cited by this paper
• Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement.

  2010cited by this paper
• Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.

  2010cited by this paper
• The frequency of hyperkalemia and its significance in chronic kidney disease.

  2009cited by this paper
• Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.

  2009cited by this paper
• Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers

  2007cited by this paper
• Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.

  2007cited by this paper
• Efficacy and safety of benazepril for advanced chronic renal insufficiency.

  2006cited by this paper
• The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.

  2005cited by this paper
• Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.

  2005cited by this paper
• National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction

  2004cited by this paper
• ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.

  2000cited by this paper
• Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

  1999cited by this paper
• Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines.

  1998cited by this paper
• Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

  1997cited by this paper
• Hyperkalemia as a complication of drug therapy.

  1987cited by this paper

• Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department

  2026cites this paper
• Safety and efficacy of novel potassium binders for chronic hyperkalemia: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Zilebesiran—Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension

  2025influential citation
• Sodium zirconium cyclosilicate (Lokelma) to enable ACEIs/ARBs use in the treatment of patients with diabetic kidney disease.

  2025cites this paper
• Hyperkalaemia in Acute Heart Failure: Patient Profiles, Predictors and Outcomes in an Asian Population

  2025cites this paper
• Blood pressure management in clinically complex scenarios: new horizons for a tailored approach.

  2025cites this paper
• Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline.

  2025cites this paper
• Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare—the DEMONSTRATE database

  2025cites this paper
• Predictors of hyperkalemia in pediatric patients on dialysis: international prospective observational study

  2025cites this paper
• Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform

  2025cites this paper
• Pathophysiology of the Antihypertensive and Cardiovascular Properties of Potassium.

  2025cites this paper
• Strategies for the Management of Cardiorenal Syndrome in the Acute Hospital Setting

  2024cites this paper
• Aldosterone and Potassium in Heart Failure: Overcoming This Major Impediment in Clinical Practice

  2024cites this paper
• Efficacy and Safety of Sodium Zirconium Cyclosilicate in the Management of Hyperkalemia in Patients with Heart Failure with Reduced and Mildly Reduced Ejection Fraction and Chronic Kidney Disease Treated with Spironolactone: rational for and design of the REGISTA-K trial.

  2024cites this paper
• New strategies for the treatment of hyperkalemia.

  2024cites this paper
• Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy – a retrospective register-based study

  2024cites this paper
• Outcomes in Older Inpatients with Hyperkalemia: A Follow-up Observational Study

  2024cites this paper
• Salt substitute recommendations for heart failure patients may influence guideline‐directed medical therapies titration

  2024cites this paper
• Comparison of the Efficacy and Tolerability of Candesartan Cilexetil between Hypertension patients of Muna and Tolaki Ethnicity

  2024cites this paper
• Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use

  2024cites this paper
• Heart Failure in CKD Population

  2024influential citation
• Consensus statement on the management of hyperkalaemia—An Asia–Pacific perspective

  2024cites this paper
• Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem

  2024influential citation
• Outcomes in Patients with Cardiometabolic Disease Who Develop Hyperkalemia While Treated with a RAAS Inhibitor.

  2023cites this paper
• Ultrasensitive Ionophore-Based Liquid Sensors for Colorimetric Ion Measurements in Blood.

  2023cites this paper
• Hyperkalemia in CKD: an overview of available therapeutic strategies

  2023cites this paper
• Frequency Of Hyperkalaemia In Non-Dialysis Dependent Chronic Kidney Disease (CKD) Patients

  2023cites this paper
• Potassium homeostasis - Physiology and pharmacology in a clinical context.

  2023cites this paper
• Self-Calibrated Ion-Selective Electrodes.

  2023cites this paper
• Biomarkers to Guide Medical Therapy in Primary Aldosteronism.

  2023cites this paper
• The Impact of Potassium Binders on Mortality in Patients with Hyperkalemia: A Single-Center Study

  2023cites this paper
• Understanding and Treatment Strategies of Hypertension and Hyperkalemia in Chronic Kidney Disease

  2023cites this paper
• Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes in Chronic Kidney Disease: A Systemic Review and Meta-Analysis

  2023cites this paper
• Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure

  2023cites this paper
• Multiple comorbid conditions and healthcare resource utilization among adult patients with hyperkalemia: A retrospective observational cohort study using association rule mining

  2022cites this paper
• Laboratory monitoring to reduce adverse drug-related events: a mixed methods study

  2022cites this paper
• SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study.

  2022cites this paper
• Emergency Department Presentation of Life-threatening Symptomatic Hyperkalemia From an Angiotensin Receptor Blocker in a Low-risk Individual.

  2022cites this paper
• The effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in critically ill patients with acute kidney injury: An observational study using the MIMIC database

  2022cites this paper
• Treatment of Presumed Hyperkalemia in the Prehospital Setting

  2022cites this paper
• Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers

  2022cites this paper
• Hypokalaemia associated with hydrochlorothiazide used in the treatment of hypertension in NHANES 1999–2018

  2022cites this paper
• Association of Serum Potassium Levels with Mortality and Cardiovascular Events: Findings from the Chinese Multi-provincial Cohort Study

  2021cites this paper
• Management of Heart Failure Patient with CKD.

  2021cites this paper
• Epidemiology of hyperkalemia in CKD patients under nephrological care: a longitudinal study

  2021cites this paper
• Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.

  2021cites this paper
• Recurrent Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Treatment: Stuck between a Rock and a Hard Place.

  2021cites this paper
• The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease

  2021cites this paper
• Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker

  2021cites this paper
• Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care

  2021cites this paper
• Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population

  2021cites this paper
• Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis

  2021cites this paper
• Real-world clinical burden and economic assessment associated with hyperkalaemia in a large integrated healthcare system: a retrospective analysis

  2021cites this paper
• Initial and Recurrent Hyperkalemia Events in Patients With CKD in Older Adults: A Population-Based Cohort Study

  2021cites this paper
• Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease

  2021cites this paper
• Potentially inappropriate prescribing of cardiovascular system and antiplatelet/anticoagulant drugs among elderly patients: a Korean population-based national study

  2021cites this paper
• Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies

  2021cites this paper
• Hyperkalemia with RAAS Inhibition: Mechanism, Clinical Significance, and Management.

  2021cites this paper
• Hyperkalemic circulatory shock and cardiac arrest altered by therapeutic management: A case report

  2021influential citation
• Hyperkalemia management in the emergency department: An expert panel consensus

  2021cites this paper
• Possible Advantages Deriving from Patiromer Use in Hypertensive Patients Made Hyperkalemic by Renin–Angiotensin–Aldosterone Blocking Agents

  2021cites this paper
• Clinical Management of Hyperkalemia.

  2020cites this paper
• Haematological parameters and biochemical indices in patients with chronic kidney disease before haemodialysis Al-Furat Al-Awsat Governorates/Iraq

  2020cites this paper
• Predictors of Hyperkalemia and Hypokalemia in Individuals with Diabetes: a Classification and Regression Tree Analysis

  2020cites this paper
• Biochemical Nutritional Assessment in Chronic Kidney Disease

  2020cites this paper
• Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review

  2020cites this paper
• Severe Persistent Hyperkalemia with Electrocardiogram Changes in a Patient with Hyperaldosteronism

  2020cites this paper
• Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations

  2020cites this paper
• Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry

  2020cites this paper
• Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review.

  2020cites this paper
• Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review.

  2020cites this paper
• Cost‐analysis of persistent hyperkalaemia in non‐dialysis chronic kidney disease patients under nephrology care in Italy

  2020cites this paper
• Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.

  2020influential citation
• Influence of thyroid status on electrolyte profile in dogs with chronic kidney disease

  2019cites this paper
• Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing

  2019cites this paper
• Dyskalemia, its patterns, and prognosis among patients with incident heart failure: A nationwide study of US veterans

  2019cites this paper
• Epidemiology of hyperkalemia in chronic kidney disease

  2019cites this paper
• Prescription of renin‐angiotensin‐aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care

  2019cites this paper
• Acute Management of Hyperkalemia

  2019cites this paper
• Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology

  2019cites this paper
• Epidemiology of hyperkalemia in chronic kidney disease.

  2019cites this paper
• Tailoring treatment of hyperkalemia.

  2019cites this paper
• Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study

  2019cites this paper
• Acute and Chronic Hypertension: What Clinicians Need to Know for Diagnosis and Management.

  2019cites this paper
• A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology

  2019cites this paper
• The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population.

  2019cites this paper
• Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission

  2019cites this paper
• Current prescription status of antihypertensive drugs in Japanese patients with hypertension: Analysis by type of comorbidities

  2019cites this paper
• Benefits and Risks

  2019cites this paper
• Evidence-based perioperative management of patients with high serum potassium level in resource-limited areas: A systematic review

  2019cites this paper
• Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.

  2019cites this paper
• Decreased serum potassium may disturb sleep homeostasis in essential hypertensives

  2018cites this paper
• Genome-wide meta-analysis of SNP-by-ACEI/ARB and SNP-by-thiazide diuretic and effect on serum potassium in cohorts of European and African ancestry

  2018cites this paper
• 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2018cites this paper
• Recommended treatment protocols to improve management of hypertension globally: A statement by Resolve to Save Lives and the World Hypertension League (WHL)

  2018cites this paper
• A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure

  2018cites this paper
• Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

  2018cites this paper
• 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2018cites this paper
• New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors

  2018cites this paper